771581-60-3Relevant articles and documents
The discovery of a potent Nav1.3 inhibitor with good oral pharmacokinetics
Pryde,Swain,Stupple,West,Marron,Markworth,Printzenhoff,Lin,Cox,Suzuki,McMurray,Waldron,Payne,Warmus,Chapman
, p. 1255 - 1267 (2017/07/07)
In this article, we describe the discovery of an aryl ether series of potent and selective Nav1.3 inhibitors. Based on structural analogy to a similar series of compounds we have previously shown bind to the domain IV voltage sensor region of Nav channels, we propose this series binds in the same location. We describe the development of this series from a published starting point, highlighting key selectivity and potency data, and several studies designed to validate Nav1.3 as a target for pain.
HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE
-
Page/Page column 55, (2009/10/22)
The present invention relates to compounds and methods which may be useful as inhibitors of GPR119 for the treatment or prevention of metabolic, cardiovascular, and metabolic diseases.